Central pulp, a term you may not have heard of, is a macular disease of the fundus that occurs in the middle-aged population, known as central pulpy chorioretinopathy. Prevalent population: middle-aged adults, 40-50 years old, male prevalence, male:female = 3-4:1, mostly monocular. Since the onset of “mesoplasia” may be related to increased catecholamine levels and corticosteroid levels in the body, patients often have the following conditions before the onset of the disease: chronic work stress, stressful life, emotional stress, or stressful situations. These mental factors may lead to increased hormone levels in the body. In addition, people who need to take a large amount of hormones for a long time because of other diseases are prone to develop severe mesoplasm. Therefore, the “middle pulp” we see in clinical practice often occurs in the “white, bone and elite” group, i.e., white-collar, backbone and elite. These people are generally middle-aged, male, and prone to eye disease under the dual pressure of long-term work and life. Other risk factors include smoking, alcohol abuse, antibiotic use, antihistamines, autoimmune diseases, hypertension, and adrenal tumors. The typical clinical manifestations of “mid-pulp” are: Symptoms: mild loss of vision in one eye, darkening of vision, a blurred, circular, dark shadow in the center of the visual field, and a sense of obscuration in the patient. Ophthalmologic examination: a round, grayish, edematous area is seen in the macular region of the fundus. OCT and fundus angiography are typical. Treatment of “middle pulp”: Since the disease has a certain degree of self-healing, patients with the initial onset of the disease can often heal on their own after rest and recuperation, and their vision returns to normal. However, the disease is prone to recurrence. Therefore, for patients with recurrent attacks and prolonged illness, irreversible damage to visual function will result. Therefore, active treatment is required. Treatment includes: Systemic treatment: Reduce risk factors as much as possible. Ocular local treatment: 1.Conventional laser, which closes the leakage point away from the central sulcus, allowing edema absorption and vision recovery. 2. PDT treatment: terminates the choroidal hyperleakage state, closes the leaky point, and reduces recurrence.